James Hunt, MD
Family Medicine · Kalamazoo, MINPI 1043279029
Payments from drug & device makers
Across 184 payments — averaging $91.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$14K
- Novo Nordisk$646
- Pfizer$342
- GSK$206
- Boehringer Ingelheim$186
- AbbVie$172
- plus $1K from 30 others
What the payments were for
- Consulting fees$14,10084%
- Food & beverage$2,76916%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 2 | $14,100 |
| Novo Nordisk | 37 | $646 |
| Pfizer | 25 | $342 |
| GSK | 25 | $206 |
| Boehringer Ingelheim | 14 | $186 |
| AbbVie(2 entities) | 7 | $172 |
| Amgen | 7 | $109 |
| Merck | 7 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $85 |
| Novartis | 5 | $85 |
| Johnson & Johnson | 6 | $82 |
| Astellas Pharma US Inc | 4 | $80 |
| Lilly USA, LLC | 4 | $57 |
| Sanofi Pasteur Inc. | 2 | $51 |
| E.r. Squibb & Sons, L.L.C. | 2 | $49 |
| Amarin Pharma, Inc. | 3 | $49 |
| Bayer | 2 | $43 |
| Dexcom, Inc. | 2 | $38 |
| AstraZeneca | 3 | $37 |
| Shire North American Group Inc | 2 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Organon | 1 | $27 |
| Radius Health, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Abbott | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Vertex | 1 | $20 |
| Bristol Myers Squibb | 1 | $20 |
| Boston Scientific | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Gilead | 1 | $13 |
| Circassia Inc. | 1 | $12 |
How this compares
$16,869 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 207 | $277,630 |
| TrulicityDulaglutide | 123 | $146,274 |
| JardianceEmpagliflozin | 96 | $134,216 |
| EliquisApixaban | 125 | $125,583 |
| OzempicSemaglutide | 101 | $123,173 |
| FarxigaDapagliflozin Propanediol | 119 | $107,409 |
| RybelsusSemaglutide | 73 | $86,627 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 81 | $74,564 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 34 | $54,703 |
| JanuviaSitagliptin Phosphate | 26 | $29,513 |
| XareltoRivaroxaban | 31 | $27,003 |
| MyrbetriqMirabegron | 26 | $24,212 |
| DescovyEmtricitabine/Tenofov Alafenam | 11 | $23,834 |
| OxycontinOxycodone Hcl | 24 | $16,767 |
| Atorvastatin Calcium | 858 | $15,472 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $57 | $423,903330 claims |
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $646 | $264,504208 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Stiolto Respimat | $186 | $145,687119 claims |
| PfizerEliquis | $342 | $125,583125 claims |
| AstraZenecaFarxiga | $37 | $107,409119 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $206 | $91,641123 claims |
| MerckJanuvia | $96 | $29,51326 claims |
| Johnson & JohnsonXarelto | $82 | $27,00331 claims |
| Astellas Pharma US IncMyrbetriq | $80 | $24,21226 claims |
| GileadDescovy | $13 | $23,83411 claims |
| AbbVieQulipta | $172 | $12,23412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Kalamazoo
- Theresa KordishKalamazoo$148K
- Eric HouchinKalamazoo$59K
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.